The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively

Biomarkers

Volumn 18, Issue 8, 2013, Pages 655-659

  Szadkowska, Iwona ^a   Wlazel, Rafal Nikodem ^a   Migala, Marta ^a   Bajon Laskowska, Karolina ^a   Szadkowski, Krzysztof ^a   Zielińska, Marzenna ^a   Paradowski, Marek ^a   Pawlicki, Lucjan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atherosclerosis; Biomarkers; Coronary artery disease; Prognosis

Indexed keywords

C REACTIVE PROTEIN; GALECTIN 3;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; BIOLOGICAL MARKERS; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE;

EID: 84889793164     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.840801     Document Type: Article

References (25)

1. De Boer RA, Lok DJA, Jaarsma T, et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60-8
2. Dutta P, Courties G, Wei Y, et al. (2012). Myocardial infarction accelerates atherosclerosis. Nature 487:325-9
3. Falcone C, Lucibello S, Mazzucchelli I, et al. (2011). Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 24: 905-13
4. Felker GM, Fiuzat M, Shaw LK, et al. (2012). Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION Study. Circ Heart Fail 5:72-8
5. Galkina E, Ley K. (2009). Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol 27:165-97
6. Gierlotka M, Gäsior M, Wilczek K, et al. (2012). Temporal trends in the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction in Poland from 2004-2010 (from the Polish Registry of Acute Coronary Syndromes). Am J Cardiol 109: 779-86
7. Hansson GK. (2005). Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-95
8. Hansson GK, Robertson AL, Söderberg-Nauclér C. (2006). Inflammation and atherosclerosis. Ann Rev Pathol 1:297-329
9. Henderson NC, Mackinnon AC, Farnworth SL, et al. (2006). Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060-5
10. Henderson NC, Mackinnon AC, Farnworth SL, et al. (2008). Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172:288-98
11. Katsuda S, Kaji T. (2003). Atherosclerosis and extracellular matrix. J Atheroscler Thromb 10:267-74
12. Lan T-H, Huang X-Q, Tan H-T. (2013). Vascular fibrosis in atherosclerosis. Cardiovasc Pathol 22:401-7
13. Libby P, Ridker PM, Hansson GK. (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 473:317-25
14. Lin YH, Lin LY, Wu YW, et al. (2009). The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96-9
15. Lok DJA, van der Meer P, Pieta W, et al. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol 99: 323-8
16. Lopez-Andres N, Rossignol P, Iraqi W, et al. (2012). Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (cardiac resynchronization in heart failure) trial. Eur J Heart Fail 14:74-81
17. Milonas C, Jernberg T, Lindbäck J, et al. (2010). Effect of Angiotensinconverting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol 105:1229-34
18. Moore KJ, Tabas I. (2011). Macrophages in the pathogenesis of atherosclerosis. Cell 145:341-55
19. Shah RV, Chen-Tournoux AA, Picard MH, et al. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12:826-32
20. Sharma UC, Pokharel S, van Brakel TJ, et al. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121-8
21. S ́wiätkiewicz I, Magielski P, Woźnicki M, et al. (2012). Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention. Kardiol Pol 4: 329-40
22. Szadkowska I, Pawlicki L, Kowalski J, et al. (2009). Left ventricular dysfunction and NT-proBNP levels in patients with one-vessel disease after first ST-elevation myocardial infarction treated with primary coronary angioplasty. Kardiol Pol 67:1201-6
23. Wang KF, Huang PH, Chiang CH, et al. (2013). Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction. Coron Artery Dis 24:23-8
24. Wright PA, Öhman MK, Hayasaki T, et al. (2010). Atherosclerosis and leukocyte-endothelial adhesive interactions are increased following acute myocardial infarction in apolipoprotein E deficient mice. Atherosclerosis 212:414-17
25. Yang RY, Rabinovich GA, Liu FT. (2008). Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 13:e17-39.